Trial Profile
A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Postpoliomyelitis syndrome
- Focus Therapeutic Use
- Acronyms FORCE
- Sponsors Grifols
- 22 Jan 2023 This trial has been discontinued in Netherlands and Poland (End Date: 24 Nov 2022), according to European Clinical Trials Database record.
- 21 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 19 Dec 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.